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SUMMARY
Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer models, and several
in clinical trials. Here we report that angiogenesis inhibitors targeting the VEGF pathway demonstrate anti-
tumor effects in mouse models of pancreatic neuroendocrine carcinoma and glioblastoma but concomitantly
elicit tumor adaptation and progression to stages of greater malignancy, with heightened invasiveness and in
some cases increased lymphatic and distant metastasis. Increased invasiveness is also seen by genetic
ablation of the Vegf-A gene in both models, substantiating the results of the pharmacological inhibitors.
The realization that potent angiogenesis inhibition can alter the natural history of tumors by increasing inva-
sion and metastasis warrants clinical investigation, as the prospect has important implications for the devel-
opment of enduring antiangiogenic therapies.INTRODUCTION
Judah Folkman’s long-standing vision of angiogenesis as a ther-
apeutic target (Folkman, 1971) has been increasingly validated in
both traditional transplant tumor models and genetically engi-
neered mouse models of cancer, beginning in the mid-1990s
and continuing to the present (Parangi et al., 1996; Shaked
et al., 2005). The ‘‘angiogenic switch’’ during tumor progression
(Hanahan and Folkman, 1996) is increasingly recognized as
constituting a rate-limiting secondary event in tumorigenesis
(Hanahan and Weinberg, 2000) that can be effectively targeted
as a successful therapeutic approach to treat cancer; clinically,
proof of concept has begun with the recent regulatory approvals
of three antiangiogenic therapies targeting the VEGF/VEGFR2
pathway in certain types of cancer (Folkman, 2007; Folkman220 Cancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc.and Ingber, 1992; Kerbel, 2000). Notably, like most systemic
therapies, these drugs have not produced enduring efficacy in
terms of either tumor shrinkage or dormancy (stable disease)
or long-term survival; rather, the common result is delayed
time to progression following a period of clinical benefit, which
is suggestive of an emergent resistance to the antiangiogenic
therapy (Bergers and Hanahan, 2008; Kerbel et al., 2001; Miller
et al., 2005).
Recently, experimental evidence has been developed in
support of this proposition: VEGF receptor inhibition in a mouse
model of pancreatic islet cancer reveals an initial response with
vascular dropout and tumor stasis, but tumors then adapt and
begin regrowing via a process referred to as ‘‘evasive resis-
tance,’’ based on the observed upregulation of alternative proan-
giogenic signals that include functional involvement of fibroblastSIGNIFICANCE
Angiogenesis inhibitors targeting the VEGF signaling pathway have proven to be efficacious in preclinical cancer models
and in clinical trials. While antitumoral effects and survival benefit are often evident, relapse to progressive tumor growth
typically ensues, reflecting multiple mechanisms of adaptation to antiangiogenic therapies. Our findings further implicate
angiogenesis inhibition as a driving force in tumor progression to stages of greater malignancy, reflected in heightened inva-
sion into surrounding tissue and in some cases increased lymphatic and distant metastasis. Thus, antiangiogenic therapy
that effectively inhibits neovascularization and produces antitumor effects and survival benefit can additionally alter the
phenotype of tumors by increasing invasion and metastasis. This realization motivates clinical studies to confirm and poten-
tially target this insidious consequence of antiangiogenic therapies.
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Malignant Progression in Angiogenesis Inhibitiongrowth factor (FGF) ligands (Casanovas et al., 2005). Addition-
ally, it was noted that the relapsing tumors appear to be more
invasive. Other studies have also associated increased invasive-
ness with impaired angiogenesis in the context of genetic
ablation of the hypoxia response and/or the VEGF/VEGFR path-
ways (Blouw et al., 2007; Du et al., 2008; Pennacchietti et al.,
2003).
RESULTS
Increased Invasiveness in Response to a Specific
VEGFR2 Inhibitor
To further extend our previous study of resistance to abrogation
of VEGF signaling with a function-blocking antibody against
Figure 1. Increased Invasive Phenotype after Anti-
VEGFR2 Therapy
Histological analysis and quantification of tumor invasion in
anti-VEGFR2 antibody (DC101)-treated or control immuno-
compromised tumor-bearing RIP1-Tag2 animals are pre-
sented.
(A) Histological images of tumors from control, 1-week, and
4-week treatment arms are shown in hematoxylin and eosin
staining (H&E; top row), indicating prominent invasive fronts
in the treated animals (black arrowheads); high-magnification
images of immunofluorescence staining for SV40 T antigen
(middle row), where T indicates tumor and Ac indicates
surrounding acinar tissue; and immunodetection of the vascu-
lature with anti-CD31 antibody (bottom row), where a central
view of the tumor parenchyma is shown.
(B) Quantification of tumor invasiveness represented as the
percentage of encapsulated islet tumors (IT), microinvasive
carcinomas (IC1), and fully invasive carcinomas (IC2) for the
three different treatments. Both anti-VEGFR2 treatments
show a statistically significant decrease in the percentage of
IT and a significant increase in IC2 tumors (**p < 0.01 by Krus-
kal-Wallis test).
(C) Quantification of tumor invasiveness in animals treated for
only 1 week with anti-VEGFR2 antibody and then maintained
without therapy for 1, 2, or 3 more weeks. Percentage of IT
(white bars), IC1 (gray bars), and IC2 (black bars) is shown
per treatment and time point. All treatment groups showed
statistical differences by Mann-Whitney test (p < 0.01) when
compared to the control group at the point when treatment
was started. Age-matched treated versus control statistical
analysis is shown for each time point. Note that no animals
in the control group survived to the 16 week time point.
*p < 0.05, **p < 0.01 by Mann-Whitney test.
Error bars indicate ± SD.
VEGFR2 (DC101) in the RIP1-Tag2 model of
pancreatic neuroendocrine cancer (PNET) (Casa-
novas et al., 2005), we sought to focus on the initial
onset of malignant progression to invasive islet
carcinoma. Tumor-bearing immunocompromised
RIP1-Tag2 mice treated with DC101 for a relatively
brief period of 1 week had reduced tumor vascula-
ture and volume compared to control age-matched
untreated animals, as described previously (Fig-
ure 1A and data not shown; Casanovas et al.,
2005). Nevertheless, histological analysis showed
a significantly more invasive phenotype after 1
week of treatment, an effect that was exacerbated when therapy
was maintained for 4 continuous weeks. These more aggressive
tumors had wide fronts of invasion, which prominently inter-
mingled with the surrounding acinar tissue, whereas the majority
of control tumors were predominantly encapsulated or microinva-
sive (Figure 1A, top panels). This aggravated invasive phenotype
was readily revealed by fluorescent immunostaining for a marker
of cancer cells, the SV40 T antigen oncoprotein (Figure 1A, middle
panels). Congruently, immunostaining for the tumor collagenous
capsule with anti-collagen type I antibody revealed the anti-
VEGFR2-treated tumors to have a much thinner capsule, with
areas of breakage or its complete absence (data not shown).
In order to quantify the degree of invasion, the frequency
of invasive lesions was scored in short-term (1 week) andCancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc. 221
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Tag2 animals using a three-grade nomenclature of noninvasive
encapsulated islet tumors (IT), microinvasive carcinomas (IC1),
and widely invasive carcinomas (IC2) as described previously
(Lopez and Hanahan, 2002). While control untreated animals
showed a 6% incidence of highly invasive tumors (IC2), treat-
ment with anti-VEGFR2 antibody for 1 week increased the IC2
tumor incidence to 54%, and furthermore, treatment for 4 contin-
uous weeks with this antibody led to an incidence of 62.5%
(Figure 1B). Thus, the event of increased tumor invasiveness
was already evident and significant following 1 week of antian-
giogenic treatment, and the effect persisted and increased
during longer-term continuous treatment for 4 weeks. Notably,
in some tumors from long-term anti-VEGFR2-treated animals,
tumor cells could be observed invading not only into the
surrounding acinar tissue but also into the vasculature (see
Figure S1 available online); such ‘‘vasoinvasion’’ has been
used as an indicator of poor prognosis in some human tumor
types (Offerhaus et al., 1991; Waggoner, 2003).
Persistence of the Invasive Phenotype after Cessation
of Anti-VEGFR2 Treatment
We next sought to investigate the reversibility of this heightened
invasive phenotype in the presence of angiogenesis inhibition
by assessing its persistence when the angiogenic blockade
was lifted. Thus, 1-week anti-VEGFR2-treated animals were
then maintained for an additional 1, 2, or 3 weeks without treat-
ment, and tumor invasiveness was determined at each time
point. Again, the proportion of invasive tumors was increased
after 1-week treatment, and strikingly, invasiveness remained
augmented after termination of therapy, with a 10-fold higher inci-
dence of widely invasive carcinomas persisting 1, 2, and 3 weeks
after cessation of treatment (Figure 1C). It is noteworthy that the
treated animals survived until 16 weeks of age due to the benefi-
cial effect of the 1-week therapy (which produced stable disease
for that period), whereas control untreated animals survived only
until 15 weeks of age (Figure S2). Thus, in order to rule out the
possibility that this increased invasion was due to an increased
life span of the animals and not to the inferred drug-related effect,
we also performed an age-matched comparison of the tumor
invasion incidence in treated animals versus controls at each
defined time point. Again, all anti-VEGFR2 treatment groups also
exhibited statistically significant differences when compared to
their respective age-matched control groups (Figure 1C).
Thus, the augmentation of tumor invasiveness is a rapidly
occurring event that develops within 1 week of initiating anti-
VEGFR2 therapy, producing a condition of increased malig-
nancy that persists even when the treatment is terminated.
Increased Invasiveness in Tumors Carrying
a Genetic Deletion of Vegf-A
To substantiate the hypothesis that this augmented invasive and
malignant phenotype is a result of impairing the VEGF/VEGFR2
proangiogenic signaling pathway, we asked whether a genetic
disruption of this pathway would produce a similar adaptive
response. To do so, we analyzed RIP1-Tag2 mice carrying a
tumor cell-specific deletion of the Vegf-A gene, by means of the
Cre-loxP system. We have previously shown that RIP1-Tag2/
Cre;Vegf-Afl/fl mice (b-VEGF-KO) exhibit a dramatic suppression222 Cancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc.of angiogenesis and impairment of tumor development and
growth (Inoue et al., 2002). Detailed histological observation of
the borders of b-VEGF-KO lesions revealed the tumors to be
much more irregular and invasive, encroaching into adjacent
exocrine tissue, as compared to tumors in RIP1-Tag2/Cre;
Vegf-A+/+ mice (b-VEGF-WT), a result that was further confirmed
by positive immunostaining for insulin, a marker of these islet
b cell tumors (Figure 2A). Consistent with previous observations
(Inoue et al., 2002), b-VEGF-KO lesions had remarkably fewer
blood vessels compared with their b-VEGF-WT counterparts,
and their invasive fronts had a microvessel density similar to
that of normal exocrine tissue, suggestive of a possible invasive
co-option of the neighboring normal vasculature in the exocrine
pancreas (Figures 2A and 2B). When tumor invasiveness
was quantified in both genotypes, encapsulated tumors and
both grades of invasive lesions were observed in the control
b-VEGF-WT mice, whereas, remarkably, no noninvasive tumors
were observed in the b-VEGF-KO mice (Figure 2C). Instead, all
tumors were invasive to varying degrees, even in the smaller
lesions. Taken together, these results recapitulate the effect of
the anti-VEGFR2 blocking antibody and thus confirm the speci-
ficity of the heightened invasiveness caused by the specific
disruption of the VEGF/VEGFR signaling axis.
Increased Metastasis in Response to VEGFR2 Blockade
To further determine the consequences of this augmented inva-
siveness, we next sought to determine whether anti-VEGFR2
antiangiogenic therapy was associated with a higher incidence
of tumor dissemination and metastasis formation in immuno-
competent RIP1-Tag2 mice. Recognizing the rapid time course
to end-stage disease in this model, we started the treatment
when solid tumors begin to appear (at 10 weeks of age) and
continued it for 10 days. The treatment was then discontinued,
and the animals were maintained until 16 weeks of age, when
they were sacrificed along with age-matched untreated control
animals. Gross morphology of surgically removed pancreata
revealed that anti-VEGFR2-treated animals more frequently con-
tained enlarged and hemorrhagic peripancreatic lymph nodes
(LNs). The presence of tumor metastases in these lymph nodes
was determined by hematoxylin and eosin (H&E) staining and
corroborated by immunohistochemical staining for the tumor-
specific SV40 T antigen oncoprotein (Figure 3A). Quantification
of the incidence of macroscopic LN metastasis in both treatment
groups revealed that the incidence of LN metastasis was 4-fold
higher in treated animals than in controls, with a relative risk of
4.3 [1.5–12.4] (95% confidence interval) (Figure 3B).
We next investigated the possible occurrence of distant metas-
tasis, focusing on the liver, which is a prevalent site for human
pancreatic metastases. Microscopic liver metastases were de-
tectedbyH&Estainingand furtherconfirmedby tumor-specific im-
munostaining for the T antigen oncoprotein, revealing microscopic
tumor nodules in the liver parenchyma (Figure 3A). In this case, the
incidence of animals with liver micrometastases was also 2-fold
higher in the treated animals than in controls, with a relative risk
of 2.0 [1.1–3.7] (95% confidence interval) (Figure 3B). Furthermore,
the average number of metastatic lesions in the liver was also
significantly increased (2.7-fold) in the treated animals compared
to controls (Figure 3C). We infer that death due to primary tumor
burden precluded the development of macrometastatic lesions.
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also Induces Increased Invasiveness
We further sought to determine whether these surprising adap-
tive responses occurred in the context of treatment with other
angiogenesis inhibitors. We chose to investigate a more potent
inhibitor of tumor angiogenesis, sunitinib (Sutent, Pfizer Inc.),
which effectively inhibits both VEGFR and PDGFR signaling,
a combination that we previously demonstrated to have potent
efficacy and added benefit over singular inhibition of VEGFR,
by targeting both endothelial cells and their supporting pericytes
(Bergers et al., 2003; Pietras and Hanahan, 2005). Consistent
with these results, continuous sunitinib treatment of tumor-
bearing RIP1-Tag2 mice was markedly efficacious, producing
a significant survival benefit (Figure 4A) and a 65% decrease in
tumor burden after 5 weeks of treatment when compared to
age-matched control animals (Figure 4B). Histological analysis
of animals treated for 5 weeks starting at 10 weeks of age
showed potent inhibition of angiogenesis and disruption of the
preexisting tumor vasculature, with concomitant exacerbated
invasive and more aggressive tumor phenotype (Figure 5A).
Fluorescent immunostaining for T antigen further revealed wide-
spread tumor infiltration, with apparent dissemination of tumor
cell clusters far from the primary tumor masses (Figure 5A;
Figure 2. Increased Tumor Invasion after Tumor-Specific
Vegf-A Gene Deletion
(A) Top row: H&E staining of lesions in RIP1-Tag2/Cre;Vegf-A+/+
(b-VEGF-WT; left) and RIP1-Tag2/Cre;Vegf-Afl/fl (b-VEGF-KO; middle)
mice. Middle row: insulin immunostaining reveals the tumor cells in
serial sections to the H&E images shown in the top row. Bottom
row: CD31 vessel staining (red) and DAPI nuclear staining (blue) of
tumors in a b-VEGF-WT mouse and a b-VEGF-KO mouse. Images
at right show a higher magnification of images in the middle column.
(B) Microvessel area (MVA) at the invasive front was equivalent to that
of exocrine tissue in b-VEGF-KO tumors. MVA of six tumors from four
b-VEGF-WT and b-VEGF-KO animals was determined in the tumor
‘‘border’’ as the band-like region 50 mm inside the tumor perimeter
(gray bars), the surrounding exocrine tissue (‘‘Exo’’; white bars), and
the tumor ‘‘core’’ (black bars). MVA values were standardized to those
of exocrine tissue distant from the tumors in each section. *p < 0.05.
(C) Quantification of invasiveness represented by the frequency of
each tumor grade in 27 tumors from 5 b-VEGF-KO mice (gray bars)
versus 75 tumors from 5 b-VEGF-WT mice (black bars) at 13 weeks
of age. *p < 0.05, **p < 0.01 by Mann-Whitney test.
Error bars indicate ± SD.
Figure S3). Quantification of this increased invasiveness
demonstrated that sunitinib treatment for 5 weeks more
than doubled the incidence of highly invasive tumors
(IC2) compared to control animals (Figure 5B). Notably,
the tumors in sunitinib-treated mice, while graded as
IC2, were often remarkable for the aggressive character
of their invasiveness to a degree of malignancy rarely
seen in untreated tumors (Figure S3).
Increased Metastasis in Sunitinib-Treated PNET
Tumors
To further investigate the adaptive response to potent
angiogenesis inhibition with sunitinib, peripancreatic LNs
were assessed for the presence of metastatic lesions by
H&E and by T antigen immunostaining of tissue sections
from treated animals (Figure 5C). Quantitative analysis revealed
a similar incidence of animals with LN metastasis in the suniti-
nib-treated versus control vehicle-treated groups (Figure 5D). In
contrast to the lack of effect on lymphatic metastasis in suniti-
nib-treated mice, hematogenous dissemination was prevalent
and arguably more aggressive. H&E staining confirmed by immu-
nostaining for the T antigen oncoprotein consistently showed
more abundant and larger liver micrometastases in the suniti-
nib-treated animals than in controls (Figure 5C, bottom row).
The incidence of liver micrometastases was significantly in-
creased by 3.5-fold in treated animals (c2, p < 0.05), with a relative
risk of 3.5 (95% confidence interval 0.8–14.3) (Figure 5D). When
quantified, the number of liver micrometastases per animal was
also increased by 3.7-fold in the sunitinib-treated animal group,
which showed a clear but not statistical significant tendency
when compared with control animals (Figure 5E). Thus, pancre-
atic islet tumors treated with a multitargeted kinase inhibitor
also adapt by increasing their metastatic phenotype.
VEGF Inhibitors also Evoke Increased Invasiveness
in Orthotopic Glioblastoma
These provocative observations in a mouse model of PNET
raised the question of generality to other tumor types. As a firstCancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc. 223
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malignancy in response to genetic or pharmacological angio-
genesis inhibition occurred in a second tumor type, glioblastoma
multiforme (GBM), by utilizing an orthotopic mouse model of
genetically engineered transformed mouse astrocytes (Blouw
et al., 2003; Du et al., 2008) characterized by development of
aggressive and locally invasive glioblastomas that phenocopy
the major characteristics of human glioblastomas (Berger and
Wilson, 1999). Thus, the effects of a VEGFR-selective kinase
inhibitor (SU10944, Pfizer Inc.) or the multitarget VEGFR kinase
inhibitor sunitinib were assessed along with GBM cells geneti-
cally deficient in Vegf-A gene expression (VEGF-KO GBMs)
(Blouw et al., 2003). In all three situations in which VEGF activity
was either pharmacologically or genetically impaired, the tumor
vasculature appeared thinner when compared to that of control
tumors (Figure 6A). The VEGF-KO GBMs produced a survival
advantage, consistent with our previous report (Blouw et al.,
2003), whereas the kinase inhibitors produced minimal
(SU10944) or modest (sunitinib) effects on tumor growth and
animal survival (Figure 6B), consistent with a clinical study
wherein a VEGFR kinase inhibitor transiently normalized the
tumor vessels and reduced side effects such as edema but
had little impact on GBM growth or patient survival (Batchelor
et al., 2007). The most notable consequence of all three con-
ditions of impaired VEGFR signaling in our mouse model was
Figure 3. Increased Incidence of Lymph Node and Liver
Metastasis in Anti-VEGFR2-Treated Animals
Histological analysis of lymph node (LN) and liver metastasis (Met) in
RIP1-Tag2 animals treated with anti-VEGFR2 for 10 days starting at
10 weeks of age and then left untreated until 16 weeks of age.
(A) LN and Met observed by histological H&E staining of tissue
sections from anti-VEGFR2-treated animals appear as enlarged
hemorrhaging LNs infiltrated with tumor cells and a small tumor
nodule in the liver parenchyma (left panels). Immunohistochemical
staining for the tumor marker SV40 T antigen (brown) reveals the pres-
ence of tumor cells infiltrated into a LN or in the midst of the liver paren-
chyma (right panels).
(B) Top: quantification of the incidence of animals with microscopic
liver micrometastasis and macroscopic LN metastasis in the control
(gray bars) and anti-VEGFR2-treated (black bars) treatment arms.
Bottom: contingency table relating the number and percentage of
animals in each treatment/metastasis case. Treated animals show
a statistically significant increase in the incidence of liver micrometa-
stasis and LN metastasis by the chi-square test (*p < 0.05; **p < 0.01).
(C) Quantification of the number of microscopic liver metastasis in the
anti-VEGFR2 treated (black bars) and control (gray bars) treatment
arms. Treated animals show a statistically significant increase in the
number of liver micrometastases per animal by the Mann-Whitney
test (*p < 0.05). Error bars indicate ± SEM.
alterations in the invasive phenotype of the GBM, in the
form of a more highly invasive and qualitatively distinct
tumor phenotype, with tumor cells dispersed throughout
the brain in close proximity to resident normal blood
vessels (perivascular tumor invasion), which contrasted
with the less prominent single-cell infiltrative pattern that
was typical in the control GBM tumors (Figure 6A). The
relative prevalence of the perivascular invasive mode
was assessed by counting the invading tumor cells in
proximity to vessels and by grading the extent of perivas-
cular invasion (which accounts for both single vascular-proximal
tumor cells as well as focal clumps of tumor cells clustered
around vessels). In all three cases, a significant increase in peri-
vascular tumor cell invasion was observed, but the invasive
effects were less pronounced in the case of both chemical
VEGFR inhibitors (SU10944 and sunitinib) than in VEGF-KO
GBM (Figure 6C). The differing degrees of invasion could be ex-
plained by the fact that VEGF-KO GBM cells were forced to grow
from the time of their inoculation without a cancer cell-supplied
source of VEGF, whereas WT GBM tumors were subjected to
VEGF blockade only after having formed and grown to a substan-
tive degree.
Thus, genetically or pharmacologically impaired VEGF
signaling in an orthotopic model of GBM also evokes a more
invasive and aggressive phenotype, distinct in form and yet anal-
ogous in essence to that observed in pancreatic neuroendocrine
tumors subjected to similar genetic or pharmacological VEGF
blockade.
Hypoxia Is Implicated in the Adaptive Response
To gain insight into one possible molecular mechanism for the
increased invasion and subsequent dissemination, we sought
to determine whether hypoxia developed in the treated tumors
concomitant with invasion. While in control untreated animals,
most of the tumors showed little or no hypoxia as revealed by224 Cancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc.
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animals and animals treated with anti-VEGFR2 antibody or suni-
tinib displayed multiple tumors with distinct regions of intense
hypoxia (Figure 7A). Moreover, when the incidence of hypoxic pi-
monidazole-positive tumors was quantified, both anti-VEGFR2
and sunitinib treatments showed a significant increase in
hypoxic tumors (Figure 7B). Furthermore, intense hypoxia was
evident in the disseminated liver micrometastases of the suniti-
nib-treated animals together with lack of vascularity inside the
metastatic lesions, while in control animals, the micrometasta-
ses were vascularized and showed no hypoxia (Figures 7Ag–
7Ai). Thus, the hyperinvasive and metastatic lesions that develop
in the PNET model treated with a potent angiogenesis inhibitor
exhibit marked hypoxia, suggestive of a role for the hypoxia
response system in their manifestation.
DISCUSSION
Proinvasive consequences of antiangiogenic therapy had been
described previously as a collateral to the antitumor response
in glioblastoma multiforme and were attributed to vessel co-
option by cancer cells, but with uncertain significance for thera-
Figure 4. Increased Life Span and Tumor Reduction in Sunitinib-
Treated RIP1-Tag2 Animals
(A) Kaplan-Meier survival curves in tumor-bearing RIP1-Tag2 mice (12 weeks)
treated continuously with vehicle control or sunitinib starting at 12 weeks.
While vehicle-treated mice showed a median life span of 15.2 weeks, mice
receiving continuous sunitinib treatment demonstrated a survival benefit of
7 additional weeks. (Kaplan-Meier statistic: p < 0.01.)
(B) Total tumor burden analysis in 5-week treatment trials with sunitinib or
vehicle control starting at 10 weeks of age. Gray bar shows tumor burden of
vehicle-treated RIP1-Tag2 animals, and black bar shows the statistically
significant tumor volume reduction of efficacious sunitinib therapy. Each
treatment cohort involved a minimum of ten animals per group. **p < 0.01 by
Mann-Whitney test. Error bars indicate ± SEM.peutic efficacy (Kunkel et al., 2001; Rubenstein et al., 2000).
Recently, heightened invasion has been further implicated as
a response to antiangiogenic therapy in another model of
orthotopic GBM (Gomez-Manzano et al., 2008), consistent with
these previous studies and our observations. More recently,
we reported that abrogation of VEGF signaling with a function-
blocking antibody against VEGFR2 elicits, after a period of tran-
sitory response, a bimodal resistance reaction with evident
revascularization and increased invasiveness; while the revascu-
larization was demonstrably important in the development of
resistance (Casanovas et al., 2005), the significance of the
heightened invasiveness was unclear. Here we demonstrate in
two distinct engineered mouse models of cancer (PNET and
GBM) that therapeutically efficacious antiangiogenic therapy
can elicit an adaptive-evasive response involving an augmented
invasive phenotype and, in some cases, increased dissemina-
tion and the emergence of distant metastasis (Figure 8).
Interestingly, PNET development in the context of genetic
ablation of the Vegf-A gene produced small pancreatic lesions
with increased invasiveness but without evident metastasis
(data not shown), in contrast to the case of VEGF pathway inhi-
bition. We suspect that the metastasis response is somehow
enabled by the initial presence of an angiogenic vasculature in
established solid tumors containing hyperproliferative cancer
cells that, when disrupted, fosters metastatic dissemination. In
contrast, the small avascular lesions populated by VEGF-KO
cancer cells may have failed to acquire other necessary capabil-
ities for productive dissemination. Regardless, the preclinical
trials in the PNET model unambiguously demonstrate the
enhancement of invasion and metastasis consequent to phar-
macological angiogenesis inhibition.
In the PNET model, the multitargeted inhibitor sunitinib
consistently demonstrated significantly better efficacy than
the VEGFR2-specific antibody, in regard to both tumor
shrinkage and augmented survival benefit. But in turn, sunitinib
evidently elicited a more highly invasive adaptation, with some
of the most aggressively invasive tumors observed heretofore
in this model. Thus, the more effective the VEGF/angiogenesis
inhibition, the more pronounced the adaptive progression to
heightened and altered invasiveness. Interestingly, while both
angiogenesis inhibitors enhanced liver metastasis, sunitinib
did not increase lymphatic metastasis, in contrast to the anti-
VEGFR2 antibody. This difference could be due to the differen-
tial specificity of inhibition by the two drugs: sunitinib potently
blocks not only VEGFR2 and the PDGFRs but also lymphatic
vessel-related VEGFR3 (Faivre et al., 2007; Roskoski, 2007).
An attractive hypothesis is that the specific blockade of
VEGFR3 signaling by sunitinib serves to alter the structure or
permeability of lymphatic vessels or lymph nodes, thereby
impeding formation of LN metastasis.
An intriguing paradox involving these results is raised by
previous reports in other model systems, in which VEGF-driven
angiogenesis was found to positively correlate with increased
tumor invasiveness (Skobe et al., 1997) or metastasis (Warren
et al., 1995). In contrast, our results as well as those presented
in the accompanying study by Ebos et al. (2009) in this issue of
Cancer Cell support the opposite conclusion, raising the possi-
bility that both induction and suppression of tumor angiogenesis
can exert proinvasive/prometastatic effects. We envision thatCancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc. 225
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by Treatment with a Multitargeted Angio-
genic Kinase Inhibitor
Histological analysis and quantification of tumor
invasion in RIP1-Tag2 mice treated for 5 weeks
with sunitinib compared to control vehicle-treated
mice are shown.
(A) Top row: H&E staining of control- and sunitinib-
treated tumors showing the invasive front exten-
sively intercalating into the surrounding tissue
(dashed white line), producing isolated islands of
normal exocrine tissue inside treated tumors
(white arrow). Middle row: immunofluorescence
staining for SV40 T antigen showing the widely
invasive phenotype in treated tumors, with several
fronts invading into the surrounding tissue. Bottom
row: visualization of blood vessels by intravenous
perfusion of FITC-conjugated tomato lectin
(green), revealing the effect of the antiangiogenic
treatment on the tumor vasculature.
(B) Quantification of the percentage of IT, IC1, and
IC2 tumors in vehicle- versus sunitinib-treated
animals. Sunitinib treatment shows statistically
significant decrease in IT and increase in the highly
invasive grade of tumor (IC2) by Mann-Whitney
test (*p < 0.01; **p < 0.01). Error bars indicate ±
SD.
(C) Left panels: histological analysis by H&E stain-
ing of tissue sections of lymph node and liver
metastasis from sunitinib-treated animals. Right
panels: confirmation of metastasis is shown by
immunofluorescence staining for the tumor
marker T antigen (red). The images give evidence
of tumor cells infiltrated into the lymph node or the
liver parenchyma.
(D) Top: quantification of the proportion of animals
with liver and lymph node (LN) micrometastasis
in the vehicle-treated (gray bars) and sunitinib-
treated (black bars) arms. Bottom: contingency
table listing the number and percentage of
animals in each treatment/metastasis case.
Treated animals show a 3.5-fold increase in the
incidence of liver micrometastasis by the chi-
square test (*p < 0.05).
(E) Quantification of the number of liver micrometastases in the vehicle-treated (gray bars) and sunitinib-treated (black bars) arms. The number of liver micro-
metastases was 3.7-fold increased in the sunitinib-treated group, which showed a clear but not statistically significant trend compared to control animals. Error
bars indicate ± SEM.the two effects, while related, may have distinct physiological
bases. For example, tumors that express very high levels of
VEGF (as in Skobe et al. and Warren et al.) may produce a tumor
vasculature with excessive sprouting, poor pericyte coverage,
and collectively impaired vascular integrity. Notably, Xian et al.
(2006) demonstrated that vessels with poor pericyte coverage
are prone to increased metastasis and that overexpression of
VEGF can drive intense angiogenesis with low pericyte coverage
and a hyperpermeable vasculature, which can be more permissive
for tumor cell intravasation and dissemination. On the other hand,
antiangiogenic therapy demonstrably disturbs the tumor vascula-
ture and in some cases (e.g., with sunitinib) also disrupts pericyte
coverage,and may inadditionbe indirectlyaffecting the tumor cells
by inducing a more invasive phenotype in response to hypoxia,
leading to increased intravasation and metastatic dissemination.
How might tumors become more invasive during antiangio-
genic therapy? One possibility is that tumors may elevate the226 Cancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc.activity of a preexisting invasion program that was not previously
the driving force of expansive tumor growth, given the capability
for angiogenesis. Alternatively, some tumors may switch on an
invasive growth program distinct from that arising spontaneously
during unperturbed tumor development and progression, as is
evidently the case for GBMs, in which antiangiogenic therapy
induced a phenotypic change from single-cell infiltration to
migration of cell clusters along normal blood vessels. These
observations suggest that the invasive growth program induced
in response to therapy may be qualitatively different than the
pathway used in normal tumor progression.
In this regard, genetic studies have implicated the hypoxia/
HIF-1a pathway as an instigator of invasion and metastasis
(Du et al., 2008; Pennacchietti et al., 2003). Interestingly in
the GBM model, hypoxia via consequent HIF-1 activation
induced angiogenesis and more infiltrative tumor cell behavior,
while inhibition of HIF-1 and consequent failure to respond to
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Malignant Progression in Angiogenesis InhibitionFigure 6. Effects of VEGFR-Selective Kinase Inhibitors on an Orthotopic Mouse Model of Glioblastoma Multiforme
(A) Top row: immunohistological analysis of glioblastoma multiforme (GBM) with fluorescent SV40 T antigen staining (red) on whole brain sections counterstained
with DAPI (blue). Control wild-type (WT) GBMs appear less invasive than WT GBMs treated with SU10944 or sunitinib, or VEGF-KO GBMs (purple arrowheads).
Bottom row: high-magnification images of fluorescent detection of tumor cells (anti-T antigen antibody; red) and the perfused vasculature (FITC-lectin, green). WT
GBM cells infiltrate as single cells into the brain parenchyma without associating with blood vessels (white arrowheads) or invade alongside blood vessels in the
brain (perivascular invasion; yellow arrowheads). GBMs treated with either SU10944 or sunitinib as well as VEGF-KO GBMs are more invasive and predominantly
migrate along blood vessels (yellow arrowheads).
(B) Kaplan-Meier survival curves of WT GBM-bearing mice untreated or treated with a relatively selective VEGFR inhibitor (SU10944) or a multitargeted VEGFR
inhibitor (sunitinib) starting 3 days after inoculation. The effects on survival observed with SU10944 and sunitinib treatment were minimal or modest, respectively,
and were not statistically significant.
(C) Top: grading of perivascular invasion was performed on a scale from 1 to 4, where 1 indicates minimal distant spread of tumor cells and 4 indicates substantial
and marked distant spread; this parameter indicated a significant increase in perivascular invasion in response to both pharmacological treatments and in the
VEGF-KO GBMs (**p < 0.01). Bottom: quantification of perivascular invasive mode by immunohistochemical analysis on tumor sections. Perivascular invasive
cells, counted as the number of cells in the tumor periphery tightly associated with vessels, were significantly increased by both antiangiogenic small-molecule
treatments and the genetic ablation of VEGF-KO GBM cells (**p < 0.01). Error bars indicate ± SD.hypoxia led to a blockade of angiogenesis and an exacerbated
proinvasive phenotype. Due to the degree of invasion and the
close proximity of invading tumor cells to blood vessels, these
tumors are less hypoxic (Blouw et al., 2003; Du et al., 2008),
despite the implication that hypoxia in the primary tumor drove
their switch to a hyperinvasive condition. In concordance with
the GBM results, we document herein the concomitant trig-
gering of hypoxia with increased invasion in response to antian-
giogenic therapy in the PNET model. While the concurrent
initiation of hypoxia and invasion could be a circumstantial
coincidence, a body of published evidence linking hypoxiaand invasion (Cairns et al., 2001; Pennacchietti et al., 2003;
Young and Hill, 1990) suggests that the hypoxia response
system could be involved in regulating invasion in this tumor
type as well. Additionally, other therapy-induced mechanisms
could contribute to the phenotypic progression of malignancy,
such as activation or upregulation of extracellular proteases
(e.g., matrix metalloproteinases and cathepsins), latent sig-
naling circuits (e.g., c-Met), or triggering of epithelial-to-mesen-
chymal transition programs, each of which can demonstrably
lead to more invasive and/or metastatic phenotypes and has
been linked to the hypoxia response in particular modelCancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc. 227
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nacchietti et al., 2003). The possible contributions of the
hypoxia response system and other factors to adaptation and
emergent resistance to angiogenesis inhibitors remain to be
determined and are an important topic for future research.
Figure 7. Antiangiogenic Treatment also
Provokes Hypoxia in Tumors and Liver
Micrometastases
(A) Hypoxia in islet tumors was detected by immu-
nofluorescence staining of pimonidazole adducts
in sections of pancreas (Aa–Af) or liver (Ag–Ai)
from control untreated animals (Aa and Ag),
animals receiving short-term (Ab) or long-term
(Ac) anti-VEGFR2 treatment, b-VEGF-WT (Ad)
and b-VEGF-KO (Ae) islet tumors, and sunitinib-
treated animals (Af, Ah, and Ai). (Aa)–(Ag) show
pimonidazole immunodetection (green) with blood
vessel CD31 staining (red); (Ah) shows pimonida-
zole immunodetection (green) and T antigen onco-
protein (red); (Ai) shows blood vessel MECA32
staining (green) and T antigen oncoprotein (red).
All images show nuclei counterstained with DAPI
(blue).
(B) Quantitation of the incidence of hypoxic tumors
was performed in long-term anti-VEGFR2-treated
and sunitinib-treated animals and plotted as the
percentage of pimonidazole-positive tumors per
animal compared to control animals. **p < 0.01
by Mann-Whitney test. Error bars indicate ± SEM.
Figure 8. Adaptive-Evasive Responses by Tumors
to Antiangiogenic Therapies
Schematic summary of adaptive responses to VEGF/VEGFR
inhibitors (and likely other angiogenesis inhibitors) that elicit
‘‘evasive resistance.’’ Tumors respond to VEGF/VEGFR
pathway inhibition with tumor stasis or regression and a loss
of blood vessels, but mechanisms of evasive resistance to
the antiangiogenic treatment are then induced that can vari-
ously enable revascularization via alternative proangiogenic
signals, increased local invasiveness, and/or enhanced
distant metastasis.
Translational Considerations
It must be emphasized that the three
VEGF pathway inhibitors currently ap-
proved for certain cancer types (variously
including colorectal, renal, breast, and
hepatocellular), and likely others (both
new drugs and new indications) to follow,
are markedly altering the standard of care
for these cancers. Despite their transitory
efficacy, angiogenesis inhibitors present
important therapeutic options that
constitute improvements in terms of both clinical benefit and
reduced toxicity compared to conventional agents used to treat
these diseases. Recognizing both their benefits and their limita-
tions, a pertinent question at hand is that of the broader applica-
bility of our findings to antiangiogenic therapies aimed at other228 Cancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc.
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the outcomes of antiangiogenic therapies in cancer patients.
Notably, in the accompanying paper by Ebos et al. (2009), one
of these approved angiogenesis inhibitors, sunitinib, is shown
to facilitate metastatic dissemination of both human breast
cancer cells and syngeneic melanoma in mice following either
orthotopic or intravenous inoculation; a second approved drug,
sorafenib, evidently has similar effects. Even brief week-long
antiangiogenic treatment elicited increased metastasis, much
as we observed following a similar week-long treatment with
the anti-VEGFR2 antibody in the PNET model. Collectively, the
two studies document increased invasion and/or metastasis in
four distinct mouse models of organ-specific cancer and begin
to establish a mechanistic pattern of increased invasion and
metastasis as an adaptive response to antiangiogenic therapy,
one that seems likely to be operative in certain human tumors.
In regard to the relevance of our findings in mouse models of
neuroendocrine tumors and glioblastoma to antiangiogenic
therapies for the cognate human cancers, there are currently
insufficient data about the responses of human pancreatic
neuroendocrine tumors due to both their rarity and the limited
number of patients that have been treated in clinical trials with
angiogenesis inhibitors. In the case of glioblastoma, there is
growing experience with antiangiogenic therapies, specifically
the VEGF ligand-trapping antibody bevacizumab (Fischer
et al., 2008; Narayana et al., 2009; Norden et al., 2008) and the
VEGFR1/2/3 kinase inhibitor AZD2171 (Batchelor et al., 2007).
In both cases, there seems to be a proinvasive adaptation to
antiangiogenic therapy, as suggested by magnetic resonance
imaging in a subset of GBM patients that developed multifocal
recurrence of tumors during the course of therapy with anti-
VEGF (bevacizumab) (Fischer et al., 2008; Narayana et al.,
2009; Norden et al., 2008) or AZD2171 (Batchelor et al., 2007).
Much as in the mouse GBM model, we infer that the human
glioblastoma cells could be co-opting blood vessels by invading
along them into the surrounding normal brain tissue, thereby
achieving vascular/nutrient/oxygen sufficiency while conse-
quently promoting an invasive dispersion phenotype (perivascu-
lar tumor invasion). Thus, there is reason to predict clinical
relevance of our collective observations.
How then could the improvement of survival in many clinical
trials in spite of increased invasiveness and metastasis be
explained? The increased progression-free survival (PFS) could
likely reflect the impairment of primary tumor growth, which,
while initially efficacious, is short lived, with the onset of multiple
forms of evasive resistance that would inevitably produce
a return to progressive disease. This tumor relapse would
compromise this initial benefit such that the prolongation of
PFS and even overall survival (OS) would not be particularly
robust, as is the case in many clinical trials. For example, recent
results from two randomized clinical trials with bevacizumab and
taxanes for the treatment of metastatic breast cancer (the E2100
study and the AVADO study) demonstrated small benefits in PFS
but not an OS benefit, and our results provide a possible expla-
nation for this disconnect.
Indeed, this undesirable therapy-triggered change in the
natural history of the treated tumors is convergent with emerging
examples involving other targeted therapy-driven changes, such
as the case of trastuzumab (Herceptin) therapy in HER2-positivebreast cancer patients. Although effective in its antitumor and
prosurvival effects (13 months increased life span), trastuzumab
therapy changes the course of disease progression in these
patients to one with a markedly increased incidence of brain
metastasis (Bendell et al., 2003; Clayton et al., 2004; Miller
et al., 2003; Weil et al., 2005), which is otherwise rare in untreated
patients. The companion study by Ebos et al. (2009) documents
increased metastasis in multiple organs, including the brain, in
response to the angiogenesis inhibitor sunitinib in a mouse
model of breast cancer, illustrating that convergence.
Another clinically relevant question raised by our results is
whether concomitant chemotherapy in some tumor types (e.g.,
in all currently approved indications for bevacizumab) could alter
or even abrogate this increased malignant phenotype. Both
preclinical and clinical trials investigating the effects of stan-
dard-of-care and more recent (e.g., metronomic) chemotherapy
regimens on proinvasive and prometastatic responses to anti-
angiogenic therapies are warranted.
Certainly, the characteristics and consequences of the exacer-
bated invasive-metastatic phenotype that develops in response
to treatment with angiogenesis inhibitors motivate critical
assessment in the clinical setting. Moreover, further preclinical
studies are warranted to elucidate the mechanisms of this adap-
tive-evasive resistance, so as to design and test the potential of
mechanism-based combination therapies aimed at impeding
this insidious consequence of singular antiangiogenic therapy.
EXPERIMENTAL PROCEDURES
Animal Models
RIP1-Tag2 (Hanahan, 1985), immunocompromised RIP1-Tag2;Rag1-KO
(Casanovas et al., 2005), and RIP1-Tag2/Cre;Vegf-Afl/fl mice (Inoue et al.,
2002) have been described previously. The orthotopic mouse GBM models
utilizing intracranial injection of transformed mouse astrocytes of wild-type
or Vegf-A-loxP mice have also been described previously (Blouw et al.,
2003; Du et al., 2008). Animal housing, handling, and all procedures involving
mice were approved by the University of California, San Francisco (UCSF),
Catalan Institute of Oncology, and Osaka Medical Center for Cancer and
Cardiovascular Diseases institutional committees that approve and oversee
research involving vertebrate animals, and all experiments were performed
according to each country’s guidelines governing animal care in the USA,
Spain, and Japan, respectively.
Therapeutic Trials
RIP1-Tag2 mice were treated starting at 10 or 12 weeks of age as indicated,
and immunocompromised RIP1-Tag2;Rag1-KO mice were used for long-
term DC101 treatment to avoid immune reaction against the therapeutic anti-
body. The following antiangiogenic regimens were used: (1) 1 mg/mouse twice
per week of anti-VEGFR2 blocking antibody (DC101) purified from a hybridoma
culture (American Type Culture Collection) and its control purified rat IgG
(Jackson ImmunoResearch) as described previously (Casanovas et al.,
2005) administered intraperitoneally (i.p.). (2) 40 mg/kg/day sunitinib L-malate
(Sutent, Pfizer Inc.) and its control carboxymethylcellulose vehicle formulation,
administered daily by oral gavage for 5 weeks. Tumor volume in the RIP1-Tag2
animals was measured as described previously (Inoue et al., 2002). For thera-
peutic trials in the GBM model, FVB/N Rag1-KO mice were injected intracra-
nially with 25,000 cells and treated with 150 mg/kg/day SU10944 or 40 mg/
kg/day sunitinib L-malate administered by oral gavage starting 3 days after
inoculation until moribund (average 13.5 days in both groups).
Histopathological Analyses
Pancreata and livers were either OCT embedded and frozen or fixed in buff-
ered formalin and embedded in paraffin. Antibodies used for specific tissue
immunostaining included rat monoclonal anti-mouse CD31 (clone MEC13.3,Cancer Cell 15, 220–231, March 3, 2009 ª2009 Elsevier Inc. 229
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prepared in the Hanahan laboratory), polyclonal guinea pig anti-insulin (A0564,
DAKO), and rat anti-MECA32 (550563, BD Pharmingen). For immunohisto-
chemistry, the EnVision system of labeled polymer-HRP anti-rabbit IgG (Dako-
Cytomation) was used as a secondary antibody. For immunofluorescence
detection, Alexa Fluor 488 goat anti-rat IgG and Alexa Fluor 546 goat anti-
rabbit IgG secondary antibodies were used at a dilution of 1:200. For nuclear
counterstaining, tissue sections were either mounted with Vectashield with
DAPI (Vector Laboratories) or stained with TO-PRO-3 iodide used at
a 1:1000 dilution and then mounted with Vectashield without DAPI.
Systemic perfusion of fluoresceinated lectin to visualize the functional blood
vasculature was performed as described previously (Inoue et al., 2002). Briefly,
0.1 mg of fluorescein-labeled tomato lectin (Vector Laboratories) was injected
intravenously in a total volume of 0.1 ml and allowed to circulate for 5–10 min,
followed by heart perfusion with neutral buffered formalin and tissue sample
preparation for OCT-embedded frozen sectioning.
For microvessel area (MVA) quantification, the ratio of CD31-stained area to
total area was calculated in ten randomly chosen circular spots (50 mm diam-
eter) using Lumina Vision image analysis software (Mitani Corporation). The
MVA of the region was expressed as the average ratio of these ten spots.
Hypoxia detection was performed 1 hr after i.p. injection of 60 mg/kg pimo-
nidazole using a Hypoxyprobe Plus kit (Natural Pharmacia International Inc.)
following the manufacturer’s instructions.
Invasion and Metastasis Analysis
Invasion grading in the RIP1-Tag2 model was performed as described previ-
ously (Lopez and Hanahan, 2002) from five H&E-stained sections per animal
from a minimum of five mice per treatment group. The incidence of LN/liver
metastasis was determined by scoring for presence or absence in each animal
and counting the number of liver micrometastases in five sections per animal
from a minimum of ten animals per treatment group. In the GBM model, peri-
vascular invasion was quantified by counting the number of invasive cells/clus-
ters associated with a vessel at the tumor edge (203 field) in double-stained
frozen sections with large T antigen and CD31 from 3–10 sections per 2–4
different tumor samples per group. Perivascular invasion grading of tumors
was determined by staining tumor cells with an antibody for SV40 large T
antigen on whole-brain sections, and 5–8 tumors from each group were
graded from 1 to 4, where 1 indicates minimal distant spread of tumor cells
and 4 indicates substantial and marked distant spread.
Statistical Analysis
All results were evaluated using the SPSS statistical software package. Due to
the small sample size in each analysis and the fact that not all of the data were
normally distributed, nonparametric statistical tests were used in each case
(Kruskal-Wallis, Mann-Whitney, or chi-square test).
SUPPLEMENTAL DATA
The Supplemental Data include three figures and can be found with this article
online at http://www.cancercell.org/supplemental/S1535-6108(09)00034-8.
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